ReviewClinical and experimental hepatology2025
To use or not to use: Safety of selected painkillers in patients with chronic liver diseases.
Review in Clinical and experimental hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safe and effective pain treatment for patients with chronic liver diseases (CLD) often poses a challenge in clinical practice. The widespread use of painkillers can lead to drug-induced liver injury. CLD can alter drug response by affecting drug-metabolizing enzymes and half-life, thereby impacting the strength and safety of drug use. This study reviews the safety and hepatotoxicity of selected analgesics in CLD. Paracetamol is the safest drug when used in standard doses. Metamizole is not contraindicated for short-term treatment. Non-steroidal anti-inflammatory drugs should be avoided due to their significant hepatotoxic potential. Tramadol is not recommended for cirrhosis due to its unpredictable effects. Codeine should also be avoided. Proper management includes the selection of drugs based on factors such as the type and severity of pain, duration of treatment, patient sensitivity, drug interactions, stage of liver disease, and the presence of other conditions. Patients should be closely monitored for adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.